About: Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.09 (-1.15%)
ATX ASX Amplia Therapeutics Ltd
Amplia Therapeutics Ltd share price
ATX price activity
Last Price
$0.090
Change (24hr)
-0.00 AUD (1.15%)
Volume
134.41K
Volume (4w avg)
-
Open
$0.09
Day Range
$0.09 - $0.09
Previous Close
$0.09
Last Trade
12 Nov, 2:44 am GMT+0
Delayed
12 Nov, 2:44 am GMT+0
ATX price performance
Delayed
12 Nov, 2:44 am GMT+0
ATX details
ATX Market Signals